BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
MY SITES:
FIND TRENDING STOCKS: HigherHighs.com/
FIND AND SET TRAILING STOPS: SuperTrail.io
TRADINGVIEW TIPS: YouTube.com/@zAngus
MY SITES:
FIND TRENDING STOCKS: HigherHighs.com/
FIND AND SET TRAILING STOPS: SuperTrail.io
TRADINGVIEW TIPS: YouTube.com/@zAngus
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
MY SITES:
FIND TRENDING STOCKS: HigherHighs.com/
FIND AND SET TRAILING STOPS: SuperTrail.io
TRADINGVIEW TIPS: YouTube.com/@zAngus
MY SITES:
FIND TRENDING STOCKS: HigherHighs.com/
FIND AND SET TRAILING STOPS: SuperTrail.io
TRADINGVIEW TIPS: YouTube.com/@zAngus
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.